Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in March - Earnings Summary

Kiniksa Pharmaceuticals International

03/05/2022 16:37

* Kiniksa Pharmaceuticals Ltd  KNSA.OQ  reported a quarterly
adjusted loss of 36 cents​​ per share for the quarter ended in
March. The mean expectation of three analysts for the quarter
was for a loss of 41 cents per share.
    * Revenue was $32.19 million​;  analysts expected $22.77
million. 
    * Kiniksa Pharmaceuticals Ltd's reported EPS for the quarter
was a
loss of 36 cents​.
    * The mean earnings estimate of analysts had risen by
about 17.6%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Kiniksa Pharmaceuticals Ltd shares had fallen by 5.3% this
quarter and lost 20.1% so far this year.
    * The company reported a quarterly loss of $25.21 million.
    * Wall Street's median 12-month price target for Kiniksa
Pharmaceuticals Ltd is $24.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 3 at 03:37 p.m.  ​All
figures in US dollars unless otherwise stated